Rodman & Renshaw Conference

RNS Number : 4981Y
Oxford Biomedica PLC
04 September 2009
 




For immediate release

4 SEPTEMBER 2009




OXFORD BIOMEDICA TO PRESENT AT RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE


Oxford, UK - 4 September 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that John Dawson, its Chief Executive Officer, will present at the Rodman & Renshaw Annual Global Investment Conference to be held on 9-11 September at the New York Palace Hotel in New York City. The presentation is scheduled on Thursday, 10 September at 2.50pm ET (7.50pm BST).

-Ends-



For further information, please contact:


Oxford BioMedica plc: 

John Dawson, Chief Executive Officer

Nick Woolf, Chief Business Officer


Tel: +44 (0)1865 783 000

JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson


Tel: +44 (0)20 7588 2828

Media/Financial Enquiries:

Lisa BaderoonMark Court/ Mary-Jane Elliott

Buchanan Communications


Tel: +44 (0)20 7466 5000

US Enquiries:

Thomas Fechtner

The Trout Group LLC


Tel: (646) 378 2900


Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGGGLDFZGLZM
UK 100